Naltrekson etkileşimleri

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir… (Darunavir etiketi, Kontrendikasyonlar)

John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is… (Darunavir ve kobisistat etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Opioid Antagonist: naloxegol ↑ naloxegol Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Lenakapavir etiketi, İlaç etkileşimleri)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

• Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (Metilnaltrekson etiketi, İlaç etkileşimleri)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedin etiketi, İlaç etkileşimleri)

Other opioid antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (Naloksegol etiketi, İlaç etkileşimleri)

Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

…Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin… (Nirmatrelvir ve ritonavir etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrekson etiketi, Kontrendikasyonlar)

Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (Etravirin etiketi, İlaç etkileşimleri)

Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (Lofeksidin etiketi, İlaç etkileşimleri)

Strongly consider recommending or prescribing an opioid reversal agent (e.g., naloxone, nalmefene) for the emergency treatment of opioid overdose (5.1) . (Naltrekson etiketi, Uyarılar ve önlemler)

Precipitation of Opioid Withdrawal : Opioid-dependent and opioid-using patients, including those being treated for alcohol dependence, should be opioid-free before starting naltrexone for extended-release injectable suspension treatment, and should notify healthcare providers of any recent opioid use. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Naltrekson etiketi, Uyarılar ve önlemler)

The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Naltrekson etiketi, Uyarılar ve önlemler)

The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrekson etiketi, Uyarılar ve önlemler)

The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (Akamprosat etiketi, İlaç etkileşimleri)

Narcotic Analgesics: buprenorphine/ naloxone ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone No dosage adjustment of buprenorphine/naloxone is required upon coadministration with GENVOYA. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (Emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)